

# Are These Pennies Heads Up? (EPAZ, LPCN, XALL, ARDS)

NEWS RELEASE BY RAZORPITCH EPAZ

**Naples, FL | March 14, 2023 05:00 AM Eastern Daylight Time**

Penny stock trading is a high-risk, high-reward world that can be incredibly exciting for investors looking for the next big thing. While many investors may focus on well-known stocks listed on major exchanges, there are countless low-priced stocks that are currently trading and may hold promising investment potential.

Today, we're diving into the world of penny stocks and taking a closer look at four stocks that are currently trading below the penny stock threshold at attractive prices. These stocks have the potential to experience explosive growth, and if you're willing to take on some risk, investing in them could pay off big time.

Investing in penny stocks may be risky, but it also presents a thrilling opportunity to invest in promising companies at a low price. As investors, it's important to carefully analyze the potential of each stock and assess its long-term prospects. So, let's dive into the first stock that's caught our eye: Epazz Inc (OTC:EPAZ).

**Epazz, Inc. (OTC: EPAZ)** is a provider of cutting-edge drone technology, blockchain mobile apps, and cloud-based business software solutions that are critical to modern business. Recently, the company received a utility patent for their AI-predictive drone Smart Charging Pad, allowing them to apply for international patents using established U.S. patent treaties in countries such as Ukraine, the United Kingdom, the European Union, Canada, Australia, South Africa, and Brazil.

Epazz's Smart Charging Pad is a game-changer in the drone charging arena. Competitors charge exorbitant prices for charging pads for drones weighing less than 55 pounds, ranging from \$4,000 to \$15,000. However, the ZenaDrone Smart Charging Pad, which can charge the ZenaDrone 1000 weighing over 250 pounds, will be priced at less than \$15,000, making it significantly more affordable.

The ZenaDrone Smart Charging Pad has built-in computer vision that allows it to understand its environment and choose the best option for receiving energy. It can be powered by solar panels or wind power, making it an environmentally friendly choice. This pad enables the ZenaDrone 1000 to land on the charger for automatic charging, allowing it to operate in remote areas in a true autonomous fashion.

The ZenaDrone 1000, equipped with updated artificial intelligence (AI) predictive automation software, is designed for use in military, oil and gas, and agriculture industries. With its affordable

offerings and advanced technology, Epazz is quickly gaining attention.

Moreover, the company recently submitted Phase 1 SBIR proposals to the U.S. government, and if awarded, EPAZ could secure significant government contracts worth up to \$15 million over the following three years. The ZenaDrone's potential for big revenue, along with the expanding U.S. Military drone segment, makes Epazz a compelling penny stock for any investor seeking a promising opportunity.

Pivoting to a completely different sector, **Lipocine Inc. (NASDAQ: LPCN)** is a pioneering clinical-stage biopharmaceutical company that is dedicated to addressing metabolic and endocrine disorders. On Monday, the stock finished up 26.83% percent attempting to make up the ground it lost on Friday.

With its cutting-edge proprietary technology platform, Lipocine is committed to developing innovative oral delivery methods to enhance the efficacy of therapeutics for the treatment of various CNS disorders.

The company currently has several candidates in development and is actively exploring potential partnerships for its promising product pipeline. As a leader in the field of biopharmaceuticals, Lipocine is poised to make a significant impact in the treatment of a wide range of diseases, making it an exciting prospect for investors looking to get in on the ground floor of a potential game-changing company.

On March 13, LPCN announced that its Board of Directors declared a dividend of one one-thousandth of a share of newly designated Series B Preferred Stock, par value \$0.0001 per share, for each outstanding share of the Company's common stock held of record as of 5:00 p.m. Eastern Time on March 24, 2023.

The shares of Series B Preferred Stock will be distributed to such recipients at 5:00 p.m. Eastern Time on March 24, 2023. The release also noted, "The outstanding shares of Series B Preferred Stock will vote together with the outstanding shares of the Company's common stock, as a single class, exclusively with respect to a reverse stock split, as well as any proposal to adjourn any meeting of stockholders called for the purpose of voting on the reverse stock split, and will not be entitled to vote on any other matter, except to the extent required under the Delaware General Corporation Law."

**Xalles Holdings Inc. (OTC: XALL)** is a holding company that invests in innovative fintech businesses. The firm is actively seeking acquisition targets with strong management teams, appealing business models, large markets, and lucrative exit opportunities.

XALL focuses on delivering industry-leading financial reconciliation and auditing solutions using blockchain and other cutting-edge technologies, resulting in a long-term recurring revenue stream.

On March 13, Xalles announced that it had reached an agreement to acquire InnovationsHR, Inc. Texas-based InnovationsHR is a technology-driven business with aspirations to completely transform the Professional Employer Organization (PEO) market.

InnovationsHR has partnered with Ovation Health Plan, which has been recognized as a leader in healthcare innovation, and is on track to become the only licensed PEO in Texas with the ability to self-insure. To differentiate itself from other PEOs, InnovationsHR offers a variety of services that employers can select from with predetermined costs and aims to provide complete transparency to its customers. According to the release, InnocationsHR is expected to generate approximately \$20 million in revenue in 2023, contributing to the company's growth and increasing its market presence.

The last stock that performed exceptionally well on Monday is **Aridis Pharmaceuticals, Inc. (NASDAQ ARDS)**. Aridis is a biopharmaceutical company that specializes in developing additional treatments for bacterial infections. Monday saw the stock close 18.66% up.

The company's primary focus is on developing clinical-stage monoclonal antibodies (mAbs) that target bacteria that cause serious infections such as ventilator-associated pneumonia (VAP) and hospital-acquired pneumonia (HAP), as well as preclinical antiviral mAbs.

Monday's success followed news that ARDS announced preliminary top-line results from their randomized, double-blind, placebo-controlled Phase 2a study of AR-501. This study evaluated the safety and pharmacokinetics of three ascending doses of AR-501 administered as an inhaled aerosol in cystic fibrosis (CF) patients.

"We are very pleased to see the safety and tolerability that we had observed in healthy volunteers also confirmed in CF patients," said Hasan Jafri, MD, Aridis Chief Medical Officer. "The high drug level achieved in the lungs, along with low systemic exposure from inhaled delivery, effectively overcome the limitations of conventional intravenous delivery and provides a strong basis for a large efficacy study in CF and other lung infections."

This attractive safety profile of AR-501, combined with the recent results from the company's AR-301 mAb Phase 3 program in older adults with ventilator-associated pneumonia, provides Aridis with two promising first-in-class, novel anti-infectives.

Razorpitch Inc. is a marketing communications and investor relations firm serving private, pre-IPO, and public companies. RazorPitch specializes in corporate, investor, and stakeholder communications. Our goal is to raise visibility, expand awareness, and increase value. To learn more, visit **RazorPitch.com**.

Disclaimers: The Private Securities Litigation Reform Act of 1995 provides investors a safe harbor in regard to forward-looking statements. Any statements that express or involve discussions with respect to predictions, expectations, beliefs, plans, projections, assumptions, objectives, goals, assumptions of future events or performance are not statements of historical fact may be forward looking statements. Forward looking statements are based on expectations, estimates, and projections at the time the statements are made that involve a number of risks and uncertainties which could cause actual results or events to differ materially from those presently anticipated. Forward looking statements in this action may be identified through use of words such as projects, foresee, expects, will, anticipates, estimates, believes, understands, or that by statements, indicating certain actions & quotes; may, could or might occur Understand there is no guarantee past performance is indicative of future results. Investing in micro-cap or growth securities is highly speculative and carries an extremely high degree of risk. It is possible that an investor's investment may be lost or due to the speculative nature of the companies profiled. RazorPitch is responsible for the production and distribution of this content. RazorPitch is not operated by a licensed broker, a dealer, or a registered investment advisor. It should be expressly understood that under no circumstances does any information published herein represent a recommendation to buy or sell a security.

## **Contact Details**

Mark McKelvie

+1 585-301-7700

[markrmckelvie@gmail.com](mailto:markrmckelvie@gmail.com)

## **Company Website**

<http://razorpitch.com>

# Tags

- EPAZ
- LPCN
- XALL
- ARDS
- EPAZZ INC. (OTC: EPAZ)
- LIPOCINE INC. (NASDAQ: LPCN)
- XALLES HOLDINGS INC. (OTC: XALL)
- ARIDIS PHARMACEUTICALS INC. (NASDAQ ARDS)
- EPAZ STOCK
- LPCN STOCK
- XALL STOCK
- ARDS STOCK
- LIPOCINE STOCK
- XALLES STOCK
- ARDIS STOCK
- EPAZZ STOCK
- LIPOCINE LPCN
- XALLES XALL
- ARDIS ARDS
- EPAZZ EPAZ